Clinical Study
Lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage 2 or 3 and consists of 2 sequential parts, Part 1 and Part 2, with the following primary objectives and primary endpoint for the definition of treatment effects.
For more information contact:
Sophia Schuman
sophia.schuman@hsc.utah.edu
801-581-7802
IRB#: IRB_00145070
| PI: Juan Gallegos-Orozco
| Department: GASTROENTEROLOGY
| Approval Date: 2022-06-08 06:00:00
Specialties: Gastroenterology
Who can participate?
Gender: All
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Will I be paid for my time?
Yes